{"organizations": [], "uuid": "b75634ab6566ffed0a954f65644f574ea26f5b21", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/gsk-ma-pharmaceuticals/gsk-grabs-roche-cancer-expert-to-lead-pharma-pipeline-deals-idUSL8N1RV47H", "country": "US", "domain_rank": 408, "title": "GSK grabs Roche cancer expert to lead pharma pipeline deals", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.985, "site_type": "news", "published": "2018-04-18T21:25:00.000+03:00", "replies_count": 0, "uuid": "b75634ab6566ffed0a954f65644f574ea26f5b21"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/gsk-ma-pharmaceuticals/gsk-grabs-roche-cancer-expert-to-lead-pharma-pipeline-deals-idUSL8N1RV47H", "ord_in_thread": 0, "title": "GSK grabs Roche cancer expert to lead pharma pipeline deals", "locations": [], "entities": {"persons": [{"name": "kevin sin", "sentiment": "negative"}, {"name": "louise heavens", "sentiment": "none"}, {"name": "ben hirschler", "sentiment": "none"}], "locations": [{"name": "london", "sentiment": "none"}, {"name": "san francisco", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "glaxosmithkline", "sentiment": "negative"}, {"name": "roche", "sentiment": "negative"}, {"name": "gsk", "sentiment": "negative"}, {"name": "genentech", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON, April 18 (Reuters) - GlaxoSmithKline said on Wednesday it had hired Kevin Sin from Rocheâ€™s Genentech unit to head worldwide business development for pharmaceuticals research and development.\nSin, who will join GSK in San Francisco in July, has been responsible for oncology deal-making at Genentech since 2010. He will play a pivotal role as the British drugmaker seeks to strengthen its drug pipeline through acquisitions and licensing deals. (Reporting by Ben Hirschler, editing by Louise Heavens)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T21:25:00.000+03:00", "crawled": "2018-04-19T15:06:47.000+03:00", "highlightTitle": ""}